{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-019669","form_type":"8-K","ticker":"RXST","cik":"0001111485","company_name":"RxSight, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.972632+00:00","generated_at":"2026-06-15T08:08:08.631960+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"RxSight Q1 revenue $17.5M (+96% YoY); raises FY2023 revenue and margin guidance","bullets":["Revenue $17.5M, up 96% YoY; gross margin improved to 59% from 42%.","Net loss $(13.2)M ($0.42/share) vs $(17.6)M loss a year ago; adjusted loss $(0.31)/share.","LAL procedure volumes 10,523 (+153% YoY); LDD installed base grew to 456 units (+85% YoY).","Raised ~$64.5M net proceeds from equity offerings; cash & investments $153.9M.","FY2023 guidance raised: revenue $79-84M (prior $78-83M); gross margin 56-58% (prior 52-54%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-019669","json":"https://secwatch.observer/filing/0000950170-23-019669.json","markdown":"https://secwatch.observer/filing/0000950170-23-019669.md","text":"https://secwatch.observer/filing/0000950170-23-019669.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/rxst-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:08:08.631960+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2159da08ff6677ebebf7c371288931a90a036597","claim":"RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).","evidence_excerpt":"In the first quarter of 2023, total revenue was $17.5 million, an increase of 96% compared to $8.9 million in the first quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"17.5 million"},{"label":"Net income","value":"(13.2) million"},{"label":"EPS","value":"(0.42)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"2159da08ff6677ebebf7c371288931a90a036597","claim":"RxSight, Inc. reported first quarter 2023 results: revenue 17.5 million, net income (13.2) million, EPS (0.42).","evidence_excerpt":"following cataract surgery, today reported financial results for the three months ended March 31, 2023. Key Quarterly Highlights • Reported first quarter 2023 revenue of $17.5 million, an increase of 96% compared to the first quarter of 2022, reflecting: • The sale of 56 Light Delivery Devices (LDDTMs), representing a 40% increase in unit sales compared to the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1111485/000095017023019669/0000950170-23-019669-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2023"},{"label":"Revenue","value":"17.5 million"},{"label":"Net income","value":"(13.2) million"},{"label":"EPS","value":"(0.42)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}